SNDX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 113752 min ago

@ $22.05

Wydano: 14 vas. 2024 @ 22:38

Zwrot: 0.00%

Poprzedni sygnał: vas. 13 - 22:50

Poprzedni sygnał: Sprzedaż

Zwrot: 4.26 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	583 893
Średni wolumen	1.10M
Kapitalizacja rynkowa	1.87B
EPS	$0 ( 2024-02-27 )
Następna data zysków	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.40
ATR14	$0.0150 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Metzger Michael A	Buy	214 500	Stock Options (Right to buy)
2024-02-07	Metzger Michael A	Buy	39 000	Common Stock
2024-02-07	Metzger Michael A	Buy	107 250	Common Stock
2024-02-07	Goldan Keith A.	Buy	70 000	Stock Options (Right to buy)
2024-02-07	Goldan Keith A.	Buy	11 700	Common Stock

INSIDER POWER
46.06
Last 97 transactions
Buy: 2 711 593 \| Sell: 1 085 664

Wolumen Korelacja

Długi: -0.03 (neutral)

Krótki: 0.43 (neutral)

Signal:(67.581) Neutral

Syndax Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
IDLB	0.85
NWS	0.846
NWSA	0.832
ARVN	0.824
BAFN	0.824
CENTA	0.821
ISDX	0.821
CVCY	0.817
ADRE	0.817
CIGI	0.812

10 Najbardziej negatywne korelacje
VERX	-0.833
RMRM	-0.832

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Syndax Pharmaceuticals Korelacja - Waluta/Towar

0.88
( strong )

0.69
( moderate )

0.00
( neutral )

0.75
( moderate )

0.39
( neutral )

0.13
( neutral )

Syndax Pharmaceuticals Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-12 000.00 (0.00 %)
EPS:	$-2.98

FY	2023
Przychody:	$0
Zysk brutto:	$-12 000.00 (0.00 %)
EPS:	$-2.98

FY	2022
Przychody:	$0
Zysk brutto:	$-454 000 (0.00 %)
EPS:	$-2.37

FY	2021
Przychody:	$139.71M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$0.480

Financial Reports:

No articles found.

Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Aktualne aktualizacje dla Syndax Pharmaceuticals [SNDX]

Upcoming Earnings Alert